Scholarlink

<p>Prostate specific membrane antigen (PSMA) Lutetium-177 (Lu-177) therapy is a relatively new theranostic treatment using a targeted radioligand therapy in the treatment of metastatic prostate cancer. PSMA-Lu177 has been approved by the FDA for treatment of prostate cancer in the metastatic castrate resistant setting. Here, we present the case of a 90-year-old man with metastatic castrate resistant prostate cancer (mCRPC) and primary resistance to androgen deprivation, second-generation androgen receptor inhibitors, and docetaxel chemotherapy. Despite the lack of response to prior lines of therapy, the patient demonstrated a rapid response to PSMA-Lu177 therapy with a substantial drop in PSA level, starting from the first cycle.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

De Novo high-volume metastatic prostate cancer with primary resistance to standard systemic therapy and exceptional response to PSMA-Lu177: A case report

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年12月12日

查看全文
  • Desiree Rafizadeh,
  • D. Kaakour,
  • S. Sun,
  • J. Herman,
  • T. Kain,
  • A. Rezazadeh Kalebasty

摘要

Prostate specific membrane antigen (PSMA) Lutetium-177 (Lu-177) therapy is a relatively new theranostic treatment using a targeted radioligand therapy in the treatment of metastatic prostate cancer. PSMA-Lu177 has been approved by the FDA for treatment of prostate cancer in the metastatic castrate resistant setting. Here, we present the case of a 90-year-old man with metastatic castrate resistant prostate cancer (mCRPC) and primary resistance to androgen deprivation, second-generation androgen receptor inhibitors, and docetaxel chemotherapy. Despite the lack of response to prior lines of therapy, the patient demonstrated a rapid response to PSMA-Lu177 therapy with a substantial drop in PSA level, starting from the first cycle.